Haemonetics CorporationHaemonetics CorporationHaemonetics Corporation

Haemonetics Corporation

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪3.92 B‬USD
‪117.56 M‬USD
‪1.31 B‬USD
‪50.61 M‬
Beta (1Y)
0.97
Employees (FY)
‪3.66 K‬
Revenue / Employee (1Y)
‪357.96 K‬USD
Net income / Employee (1Y)
‪32.15 K‬USD

About Haemonetics Corporation


CEO
Christopher A. Simon
Headquarters
Boston
Founded
1971
FIGI
BBG000C7TF41
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Analyze a symbol's price movements over past years with our seasonal tools, helping you spot repeating annual trends and better gauge potential market patterns.

Frequently Asked Questions


The current price of HAE is 76.11 USD — it has decreased by −0.74% in the past 24 hours. Watch Haemonetics Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Haemonetics Corporation stocks are traded under the ticker HAE.
HAE stock has fallen by −3.12% compared to the previous week, the month change is a 3.93% rise, over the last year Haemonetics Corporation has showed a −16.33% decrease.
We've gathered analysts' opinions on Haemonetics Corporation future price: according to them, HAE price has a max estimate of 125.00 USD and a min estimate of 85.00 USD. Watch HAE chart and read a more detailed Haemonetics Corporation stock forecast: see what analysts think of Haemonetics Corporation and suggest that you do with its stocks.
HAE reached its all-time high on Feb 9, 2021 with the price of 142.11 USD, and its all-time low was 5.78 USD and was reached on May 10, 1991. View more price dynamics on HAE chart.
See other stocks reaching their highest and lowest prices.
HAE stock is 2.06% volatile and has beta coefficient of 0.97. Track Haemonetics Corporation stock price on the chart and check out the list of the most volatile stocks — is Haemonetics Corporation there?
Today Haemonetics Corporation has the market capitalization of ‪3.92 B‬, it has decreased by −2.29% over the last week.
Yes, you can track Haemonetics Corporation financials in yearly and quarterly reports right on TradingView.
Haemonetics Corporation is going to release the next earnings report on Nov 7, 2024. Keep track of upcoming events with our Earnings Calendar.
HAE earnings for the last quarter are 1.02 USD per share, whereas the estimation was 1.01 USD resulting in a 1.44% surprise. The estimated earnings for the next quarter are 1.07 USD per share. See more details about Haemonetics Corporation earnings.
Haemonetics Corporation revenue for the last quarter amounts to ‪336.17 M‬ USD, despite the estimated figure of ‪335.08 M‬ USD. In the next quarter, revenue is expected to reach ‪342.61 M‬ USD.
HAE net income for the last quarter is ‪38.37 M‬ USD, while the quarter before that showed ‪20.37 M‬ USD of net income which accounts for 88.41% change. Track more Haemonetics Corporation financial stats to get the full picture.
No, HAE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 10, 2024, the company has ‪3.66 K‬ employees. See our rating of the largest employees — is Haemonetics Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Haemonetics Corporation EBITDA is ‪298.70 M‬ USD, and current EBITDA margin is 23.33%. See more stats in Haemonetics Corporation financial statements.
Like other stocks, HAE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Haemonetics Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Haemonetics Corporation technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Haemonetics Corporation stock shows the sell signal. See more of Haemonetics Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.